Understanding the Genes Behind Breast Cancer: A Closer Look at Hereditary Risks

Breast cancer is not just a health issue; it is a growing concern that affects millions of women worldwide, and India is no exception. In recent years, breast cancer has surged to become the most common cancer among Indian women, overtaking cervical cancer, which held that title for decades. According to the latest statistics, breast cancer accounted for a staggering 13.5% of all new cancer cases in India in 2020, translating to approximately 178,361 diagnoses. This surge in incidence is particularly concerning as it reflects a nearly 50% increase from previous decades, with a growing number of cases being diagnosed in younger women. The implications are profound; not only does this trend indicate a rising health crisis, but it also highlights the urgent need for enhanced awareness, early detection, and effective treatment strategies to combat this disease that affects so many lives.

Hereditary vs. Sporadic Breast Cancer: What You Need to Know

When it comes to breast cancer, understanding the difference between hereditary and sporadic cases is key! Hereditary breast cancer is like a family heirloom, passed down through generations due to inherited gene mutations, such as BRCA1 and BRCA2, which can significantly increase your risk—up to 70%! On the other hand, sporadic breast cancer is more like a surprise guest; it occurs randomly due to mutations that develop during a person’s life, often influenced by lifestyle or environmental factors. While hereditary cases tend to show up earlier and can be more aggressive, sporadic cases are more common overall. Knowing whether your breast cancer risk is hereditary or sporadic can help guide your screening and prevention strategies, empowering you to take charge of your health!

Role of genes and their mutations in breast cancer risk and development

Genetics plays a crucial role in understanding breast cancer risk and development, acting as a double-edged sword. On one hand, genes like BRCA1 and BRCA2 are essential for repairing DNA and maintaining cellular health. However, when these genes mutate, their protective functions diminish, significantly increasing the likelihood of developing breast cancer. In fact, women with a BRCA1 mutation face up to a 70% risk of breast cancer by age 80, while those with a BRCA2 mutation have a risk of about 40-60%. These mutations not only elevate breast cancer risk but also raise the chances of ovarian and other cancers, making genetic awareness vital for proactive health management.

But it is not just BRCA genes that matter; other high-penetrance genes like PTEN, TP53, CDH1 and PALB2 and moderate-penetrance genes like CHECK2, ATM and BARD1 also contribute to breast cancer susceptibility. Approximately 5-10% of breast cancer cases are hereditary, meaning they stem from inherited gene changes passed down through families. Understanding one’s genetic background can be transformative, especially if there is a family history of breast cancer. 

BRCA1: The Gene That Can Change Your Breast Cancer Risk

Meet BRCA1, the superhero gene that normally helps protect your cells from becoming cancerous by repairing damaged DNA. Located on chromosome 17, BRCA1 is a vital player in maintaining genomic stability, ensuring that your cells grow and divide properly. However, when this gene mutates, it can no longer perform its protective duties effectively. This malfunction can lead to a significantly increased risk of breast cancer—women with a BRCA1 mutation face up to a jaw-dropping 70% chance of developing the disease by age 80.

BRCA2: Your Gene Guide to Breast Cancer Risks

BRCA2 is a crucial superhero gene that helps keep your cells healthy by repairing damaged DNA and preventing mutations that can lead to cancer. When functioning properly, BRCA2 acts like a diligent repairman, fixing DNA breaks and ensuring that cells grow and divide correctly. However, when mutations occur in the BRCA2 gene, this protective mechanism falters, leading to an increased risk of developing breast cancer; women with a BRCA2 mutation face a lifetime breast cancer risk of about 55% to 69%, often diagnosed at younger ages than those without such mutations.

PTEN: The Guardian Gene in Breast Cancer Risk

PTEN is a vital tumour suppressor gene that acts as a guardian for your cells, regulating growth and preventing tumours from forming. When functioning properly, PTEN helps maintain a balance in cell division and survival. However, mutations in this gene can lead to serious consequences; women with inherited PTEN mutations face an increased breast cancer risk of 67% to 85%, placing it alongside the more well-known BRCA genes in terms of hereditary cancer risks.

TP53: The Overlooked Guardian of Breast Health

TP53 is a crucial gene that acts as a guardian for your cells, helping to prevent cancer by regulating cell growth and repairing DNA damage. When mutations occur in TP53, it can lead to a significantly increased risk of breast cancer, particularly in women with inherited mutations, who face a lifetime risk of over 60%.

CDH1: The Hidden Hero in Breast Cancer Risk

CDH1 is a crucial gene that encodes for E-cadherin, a protein essential for cell adhesion, helping to keep your cells tightly bound together. When mutations occur in the CDH1 gene, it can lead to a higher risk of lobular breast cancer (LBC), with estimates suggesting a lifetime risk of 39% to 52% for women carrying these mutations. Additionally, CDH1 mutations are famously linked to Hereditary Diffuse Gastric Cancer (HDGC), making awareness of this gene vital for individuals with a family history of these cancers.

PALB2: Your Genetic Ally in Breast Cancer Awareness

PALB2 (Partner and Localizer of BRCA2) is a key player in the world of genetics, working alongside BRCA1 and BRCA2 to repair damaged DNA and keep your cells healthy. When functioning properly, PALB2 helps prevent cancer, but mutations can lead to a significantly increased risk of breast cancer—women with a PALB2 mutation face a lifetime risk of about 35% to 58% by age 70. These mutations are often associated with more aggressive forms of breast cancer, particularly triple-negative types, making early detection crucial.

CHEK2: The Moderate Risk Guardian in Breast Cancer

CHEK2 is an important gene that acts like a guardian for your cells, helping to repair DNA and prevent tumour growth. When mutations occur in CHEK2, they can increase breast cancer risk—women with these mutations have a lifetime risk ranging from 28% to 37%, especially if they have a family history of the disease. While CHEK2 mutations are not as well-known as BRCA mutations, they are actually more common and can lead to a moderate risk of breast cancer, making early screening and personalised care crucial.

ATM: The DNA Repair Specialist in Breast Cancer

ATM (Ataxia Telangiectasia Mutated) is a crucial gene that acts like a DNA repair specialist, helping to fix damaged genetic material and keep your cells healthy. When mutations occur, it can significantly increase breast cancer risk – women with this mutation face a lifetime risk of about 52%! While ATM mutations are less well-known than BRCA mutations, they are associated with a moderate risk of breast cancer and can also elevate the risk for other cancers, such as pancreatic and prostate cancer.

BARD1: Your Secret Weapon Against Breast Cancer

BARD1 is a vital gene that works alongside BRCA1 to help repair damaged DNA and maintain cellular health. When mutations occur in BARD1, particularly the p.Q564X variant, they can lead to a moderate increase in breast cancer risk, with estimates suggesting a lifetime risk of 17% to 30% for carriers. While not as famous as BRCA genes, BARD1 mutations are increasingly recognized, especially in cases of triple-negative breast cancer.

Understanding Genetic Factors in Breast Cancer: Why It Matters

Understanding the genetic factors behind breast cancer is like having a treasure map for your health! With about 5% to 10% of breast cancers being hereditary, knowing your genetic risks can empower you to make informed decisions about your health. If you have a family history of breast cancer, consider genetic counselling and testing to uncover any inherited mutations. These insights can help you and your healthcare team create a personalised screening plan and explore preventive options, giving you the tools to take charge of your health journey!

REFERENCES

1. Kulothungan, V. et al. (2024) ‘Burden of female breast cancer in India: Estimates of ylds, ylls, and dalys at national and subnational levels based on the National Cancer Registry Programme’, Breast Cancer Research and Treatment, 205(2), pp. 323–332. doi:10.1007/s10549-024-07264-3. 
2. Mehrotra, R. and Yadav, K. (2022) ‘Breast cancer in India: Present scenario and the challenges ahead’, World Journal of Clinical Oncology, 13(3), pp. 209–218. doi:10.5306/wjco.v13.i3.209. 
3. Reason for the rising number of breast cancer cases in Indian women (no date) Medanta. Available at: https://www.medanta.org/patient-education-blog/reason-for-the-rising-number-of-breast-cancer-cases-in-indian-women. 
4. Admin (2024) Breast cancer and genetics: Understanding hereditary risk factors, Galaxy Care Hospital, Pune. Available at: https://www.galaxycare.org/blog/breast-cancer-and-genetics-understanding-hereditary-risk-factors/ (Accessed: 15 October 2024). 
5. Breast cancer risk factors you can’t change (no date) Breast Cancer Risk Factors You Can’t Change | American Cancer Society. Available at: https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html (Accessed: 15 October 2024). 
6. Inherited cancer risk: BRCA mutation (2023) Johns Hopkins Medicine. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/inherited-cancer-risk-brca-mutation (Accessed: 15 October 2024). 
7. Genetics of breast and gynecologic cancers (PDQ®) (no date) Genetics of Breast and Gynecologic Cancers (PDQ®) – NCI. Available at: https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq (Accessed: 15 October 2024). 
8. Shiovitz, S. and Korde, L.A. (2015) ‘Genetics of breast cancer: A topic in evolution’, Annals of Oncology, 26(7), pp. 1291–1299. doi:10.1093/annonc/mdv022. 
9. Fu, X. et al. (2022) ‘BRCA1 and breast cancer: Molecular mechanisms and therapeutic strategies’, Frontiers in Cell and Developmental Biology, 10. doi:10.3389/fcell.2022.813457. 
10. BRCA2 gene mutations: Cancer risk (no date) Cancer Risk and BRCA2 Gene Mutations. Available at: https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca2/cancer-risk (Accessed: 15 October 2024). 
11. Kheirollah, Y., et al. (2023). The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-analysis. Biochemical Genetics.
12. Marvalim, C., Datta, A. and Lee, S.C. (2023) ‘Role of p53 in breast cancer progression: An insight into p53 targeted therapy’, Theranostics, 13(4), pp. 1421–1442. doi:10.7150/thno.81847. 
13. Bücker, L. and Lehmann, U. (2022) ‘Cdh1 (E-cadherin) gene methylation in human breast cancer: Critical appraisal of a long and twisted story’, Cancers, 14(18), p. 4377. doi:10.3390/cancers14184377. 
14. Ruberu, T.L. et al. (2024) ‘Meta‐analysis of breast cancer risk for individuals with PALB2 pathogenic variants’, Genetic Epidemiology [Preprint]. doi:10.1002/gepi.22561. 
15. Apostolou, P. and Papasotiriou, I. (2017) ‘Current perspectives on CHEK2 mutations in breast cancer’, Breast Cancer: Targets and Therapy, Volume 9, pp. 331–335. doi:10.2147/bctt.s111394. 
16. Stucci, L.S. et al. (2021) ‘The ATM gene in breast cancer: Its relevance in clinical practice’, Genes, 12(5), p. 727. doi:10.3390/genes12050727. 
17. Śniadecki, M. et al. (2020) Bard1 and breast cancer: The possibility of creating screening tests and new preventive and therapeutic pathways for predisposed women [Preprint]. doi:10.20944/preprints202009.0654.v1.

About the Author:

Katherine began her career as a genome analyst, where she delved deep into the complexities of genetic data, unravelling the mysteries of the human genome. With a passion for innovation and a keen eye for detail, she transitioned into her current role as a bioinformatics curator, where she meticulously curates single nucleotide polymorphisms (SNPs) linked to various traits. Katherine’s research enhances our understanding of how genetics influence health and behaviour, contributing to the future of personalised nutrition or medicine.